FluxMPS™ RPMI 1640 Medium, High Glucose w/o Sodium Pyruvate, Sodium Bicarbonate, Phenol Red: 1X Liquid

FluxMPS™ RPMI 1640 Medium, High Glucose w/o Sodium Pyruvate, Sodium Bicarbonate, Phenol Red: 1X Liquid

Microfluidics Suitable, quadruple-stage ultra-filtered (0.1 µm ×2 + 0.04 µm ×2) 1X liquid RPMI 1640 medium engineered for organ-on-a-chip (OoC), tissue-on-a-chip (ToC), and microphysiological system (MPS) applications. A quadruple-stage train (0.1 µm ×2 + 0.04 µm ×2) reaches a 0.04 µm final cut-off, five times finer than the 0.22 µm membranes used for conventional sterile filtration.

• Quadruple-stage nano-filtration: 0.1 µm (Prefiltration I & II) + 0.04 µm (Final filtration I & II — Polish), reaching a 0.04 µm final cut-off
• Endotoxin release specification: < 0.05 EU/mL (LAL assay, USP <85> BET)
• High-glucose RPMI 1640 base (4500 mg/L / 4.5 g/L) with 300 mg/L L-glutamine
• Formulated without sodium pyruvate, sodium bicarbonate, or phenol red — pale yellow, clear solution
• Prepared with Ultrapure Type 1 water (18.2 MΩ·cm)
• ISO Class 5 aseptic fill & finish under an ISO 13485:2016 quality management system
• Custom formulations available — pH, glucose, salts, HEPES, and nutrient composition on request

Engineered where standard media fails

Conventional 0.22 µm-filtered media carry mycoplasma-sized organisms (0.2–0.3 µm), subvisible debris, and lot-to-lot endotoxin variability that accumulate inside microchannels — corrupting biosensor readings, stressing primary cultures, and shortening device lifetimes. FluxMPS™ is built to address these failure modes at the filtration stage.

Quadruple-stage filtration system

FluxMPS™ RPMI 1640 Medium, High Glucose w/o Sodium Pyruvate, Sodium Bicarbonate, Phenol Red: 1X Liquid is processed through a four-pass filtration train — two dedicated prefilter + final-filter pairs — reaching a 0.04 µm final pore size, retaining subvisible particulates and mycoplasma-sized organisms that a single-pass 0.22 µm filter cannot address.

1. 1

   0.1 µm Prefiltration I

   Removes large particulates and protein/cellular aggregates; protects the first 0.04 µm final filter cartridge and extends its service life.

2. 2

   0.04 µm Final filtration I

   First 0.04 µm pass; retains sub-micron particulates and microaggregates, including mycoplasma-sized organisms (0.2–0.3 µm), that pass a standard 0.22 µm filter.

3. 3

   0.1 µm Prefiltration II

   Second dedicated prefilter, protecting the second 0.04 µm cartridge and providing full train redundancy.

4. 4

   0.04 µm Final filtration II — Polish

   Ultimate polishing filter; aseptic fill & finish in a validated ISO Class 5 laminar-flow workstation.

Designed for next-generation cell culture platforms

FluxMPS™ RPMI 1640 Medium, High Glucose w/o Sodium Pyruvate, Sodium Bicarbonate, Phenol Red: 1X Liquid is intended for organ-on-a-chip, metabolic research, live-cell imaging, and primary cell models where particulate load and endotoxin variability are unacceptable.

Automated Bioreactors & Robotics

An optional 0.01 µm (10 nm) ultra nano-filtered MPS Grade variant is available for automated bioreactor and robotic perfusion systems requiring the ultimate particulate exclusion.

• Total Particulate Exclusion: 10 nm filtration for nanoscale valve and sensor protection
• Valve & Sensor Protection: prevents particulate-induced blockage in precision fluidic systems
• Extended Perfusion Stability: maintains flow rate consistency across multi-week automated runs

Inquiry Required: Contact support@diagnocine.com to request the 0.01 µm MPS Grade variant.

Lot-release quality parameters

Every production lot of FluxMPS™ RPMI 1640 Medium, High Glucose w/o Sodium Pyruvate, Sodium Bicarbonate, Phenol Red: 1X Liquid undergoes the quality-release battery below before shipment.

Full composition (mg/L)

Complete formulation with CAS numbers. Total: 38 components across 4 categories. All ingredient names and mg/L values reproduced from the manufacturer specification. Custom compositions available on request.

ISO 13485:2016 manufacturing & compliance

Manufactured under an ISO 13485:2016 quality management system, with final packaging, testing, and customization at Diagnocine, Totowa, New Jersey, USA.

How DCP-RPMIG-PBR1X (FluxMPS™) compares

Side-by-side comparison against conventional 0.22 µm-filtered alternatives of a similar base formulation.

Comparison figures from published supplier specifications, accessed 2026-09-02. Suppliers that publish no numeric endotoxin specification are shown as "Not specified".

Frequently asked questions

Common questions about FluxMPS™ RPMI 1640 Medium, High Glucose w/o Sodium Pyruvate, Sodium Bicarbonate, Phenol Red: 1X Liquid.

Supporting literature

Peer-reviewed publications supporting the scientific rationale for ultra-filtered media and microfluidic cell culture applications.

1. Huh D et al. (2010). Reconstituting organ-level lung functions on a chip. Science, 328(5986), 1662–1668. doi:10.1126/science.1188302
2. Bhatia SN & Ingber DE (2014). Microfluidic organs-on-chips. Nature Biotechnology, 32(8), 760–772. doi:10.1038/nbt.2989
3. Bhattacharya S et al. (2018). Challenges in maintaining cell viability during microfluidic experiments. Electrophoresis, 39(7), 997–1006. doi:10.1002/elps.201700375
4. Warburg O (1956). On the origin of cancer cells. Science, 123(3191), 309–314. doi:10.1126/science.123.3191.309
5. Kim S et al. (2012). Gut-on-a-chip microdevice replicates key functional features of the human intestine. Lab on a Chip, 12(12), 2165–2174. doi:10.1039/c2lc40074j
6. Zhang YS et al. (2017). Multisensor-integrated organs-on-chips platform for automated in situ monitoring. PNAS, 114(12), E2293–E2302. doi:10.1073/pnas.1612906114
7. Vernetti L et al. (2017). Functional coupling of human microphysiology systems. Scientific Reports, 7, 42296. doi:10.1038/srep42296
8. Schuster B et al. (2020). Automated microfluidic platform for dynamic and combinatorial drug screening of tumor organoids. Nature Communications, 11, 5271. doi:10.1038/s41467-020-19058-4
9. Zheng F et al. (2021). Organ-on-a-chip systems: microengineering to biomimic living systems. Small, 17(7), 2004175. doi:10.1002/smll.202004175
10. Esch EW et al. (2015). Organs-on-chips at the frontiers of drug discovery. Nature Reviews Drug Discovery, 14(4), 248–260. doi:10.1038/nrd4539